Meet #TEDxNE Mind+Life conference speaker Nikta Fakhri. Nikita is an associate professor in the Deptartment of Physics at Massachusetts Institute of Technology (MIT) & the Physics of Living Systems group. Nikta will speak at conference session 2: LIFE at our event on 9/25. Register now: bit.ly/3Aw8ABy

Glad to see this published: a nuanced analysis supporting the safety of pirtobrutinib in patients requiring antithrombotic therapy. onlinelibrary.wiley.com/doi/10.1002/jh…

Pirtobrutinib in cBTKi-intolerant patients — this publication addresses one of the most clinically relevant questions in CLL.

Glad to see this published — ibrutinib-associated pericardial events across two landmark trials. onlinelibrary.wiley.com/doi/full/10.11…

If you happen to be at #ASH24 and interested, please join us for this CLL session on Friday morning: What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia | Research To Practice m.researchtopractice.com/Meetings/FSS20…

Largest data set (N=64) to date outlining outcomes of VenR post cov. BTKi in AmericanJournalofHematology #CLL #lymsm

Just out at AmericanJournalofHematology : Ven-based therapy after cBTKi in #CLL led by Nilanjan Ghosh, MD, PhD . Kudos to the CORE team and Beenish Manzoor for building the CORE registry. Looking forward to having more studies using CORE onlinelibrary.wiley.com/doi/full/10.10…

I look forward to discussing the post-ASH24 CLL advances on January 4 in Seattle!

4/ And for anyone wondering whether that Shakespeare "Toci or not toci" quote came from, here's our 2021 review of early interventions with toci. Thanks Bita Fakhri Nina Shah for mentorship with writing it! tandfonline.com/doi/10.1080/10…

Thanks Beyond Trauma Foundation for letting us do a little UCSF Helen Diller Family Comprehensive Cancer Ctr alumni reunion here - Bita Fakhri was my attending when I was a fellow!! I’ve learned so much from her about lymphoma, CAR-T, and juggling parenthood and attendinghood 🙏

⁦Stanford Hematology Division⁩ is excited to welcome Dr. Susan O’Brien to our campus today to update us on all the phenomenal developments in the treatment of #CLL ⁦⁦Stanford Department of Medicine⁩ ⁦Bita Fakhri⁩

Just out Blood Advances Acquired mutations in #CLL patients with disease progression on ALPINE trial ashpublications.org/bloodadvances/… Fred Hutch Cancer Center

Thrilled to attend my sister’s talk at Stanford tomorrow ⁦⁦Nikta Fakhri⁩: The Hidden Order of Life: How Nature Breaks Symmetry | Iranian Studies iranian-studies.stanford.edu/events/hidden-…

Just a reminder that Stanford Hematology Division is actively recruiting, details below, pls reach out with Qs, happy to chat with prospective candidates about our amazing Division, please re-post to spread the word! Stanford Department of Medicine Stanford Medicine Stanford Cancer Institute Stanford Health Care

Looking forward to this session in LA!

In our editorial on the new #LRF CLL consensus guidelines, Bita Fakhri , Nitin Jain and I highlight their value but stress the need for resource-specific guidance to address global disparities. Fred Hutch Cancer Center ashpublications.org/bloodadvances/…

Many cancer doctors are leaving academic medical centers and moving to Pharma, admin jobs, or just retiring early. This jeopardizes finding new treatments for cancer, and affects patients. ASCO ascopubs.org/doi/10.1200/JC…

Looking forward to presenting and connecting with old friends and colleagues!

📢 Just published in Blood (Blood Journals Portfolio)! “How I treat patients with #CLL after prior cBTKi and BCL2i therapy” Always great to work with my friend and colleague Matthew Davids, MD, MMSc ! 👉 doi.org/10.1182/blood.… #CLL #BloodJournal Fred Hutch Cancer Center Dana-Farber